Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of FCN-437c plus aromatase inhibitor with or without goserelin in HR-positive, HER2-negative advanced breast cancer
CTR20213286Phase 3Active
- Sponsor
- Fochon Biosciences
- Start
- Mar 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ongiciclib, letrozole, anastrozole, goserelin in breast cancer, sponsored by Fochon Biosciences. Started Mar 2022; status: active.
02
Drugs
ongiciclibletrozoleanastrozolegoserelin
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20213286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213286.